Drug Trial Radar · NCT00553631
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
Last checked: Nov 19, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Jan 29, 2008
Primary completion
May 5, 2009
Study completion May 5, 2009
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this non-inferiority study is to evaluate the efficacy and safety of GA-GCB (velaglucerase alfa) administered every other week in comparison to imiglucerase in treatment naive patients with type 1 Gaucher disease.
Conditions
- Gaucher Disease, Type 1
Interventions
velaglucerase alfaBiological
IV infusion, 60 U/kg every other week for 9 months
imigluceraseBiological
IV infusion, 60 U/kg every other week for 9 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group.Time frame: Baseline to Month 9
Locations
11 sites in 9 countries. Site status is shown where the registry gives one.
Duke Children's Hospital & Health Center
Durham, North Carolina
Your Health S.A.
Buenos Aires, Argentina
All India Institute of Medical Sciences
New Delhi, India
KEM Hospital Research Centre
Pune, India
Malabar Institute of Medical Sciences Ltd.
Calicut, Kerala, India
Shaare Zedek Medical Center
Jerusalem, Israel
Sociedad Espanola de Socorros Mutuos
Asunción, Paraguay
National Research Center for Haematology
Moscow, Russia
Hospital Universitario Miguel Servet
Zaragoza, Spain
La Rabta Hospital
Tunis, Tunisia
The Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.